2008, Number 2
Med Int Mex 2008; 24 (2)
Di Girolamo G, Tamez PAL, Tamez PHE
PDF size: 171.11 Kb.
ABSTRACTType 2 diabetes mellitus is a worldwide distributed chronic disease, with a high morbimortality. The primary treatment is to maintain a glycemia within normal limits, with glycemic hemoglobin from 6 to 7%, without hypoglycemia. Current treatment has shown to be efficient and safe in most of the cases, but only temporarily due to the progressive course of the disease. Recently, there is a new class of medicinal agent known as DPP-4 inhibitors which prevent the degradation of the incretin, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. Incretins have beneficial effects in the glycemic control through pancreatic (function and cellular mass) and extrapancreatic effects. The present review analyzes the pharmacokinetic, pharmacodynamic and safety of inhibitors of dipeptidyl peptidase and comments the significant impact they could have in the treatment of diabetes.